Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with William Gallentine, DO. [LISTEN TIME: 17 minutes]

Givinostat, a HDAC inhibitor, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial.

PREDICT-PD, a low intensity and cost-efficient assessment, was able to estimate the occurrence of motor disturbances in the future, in particular sub-threshold parkinsonism and bradykinesia.

ACP-204, an inverse agonist at the 5-HT2A receptor, builds upon the learnings of pimavanserin (Nuplazid) in the treatment of neuropsychiatric symptoms.

Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.

The director of the headache section at Cleveland Clinic’s Neurological Institute provided thoughts on how recent advances have propelled migraine care, treatment possibilities behind prevention, and emerging research targets.

Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.

The odds of making a specific diagnosis nearly doubled when the patient headache questionnaire was employed, resulting in more accurate identification and subsequent treatment of migraine cases.

Across 31 studies of patients with NMOSD, more than half of the patients included reported having sleep disturbances associated with their condition.

A panel of experts provide commentary on a range of topics regarding the integration of biosimilars in the management of multiple sclerosis, including the supporting data behind these agents and how the clinical community can adapt.

Significant associations between higher third-trimester ASM concentrations with poorer adaptive and behavior outcomes were seen on several assessments, including the Adaptive Behavior Assessment System, Third Edition.

The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.

Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.

Pixyl.Neuro, a CE-marked medical device, is designed to be integrated into the radiology workflow, providing clinicians with diagnostic support of neuroinflammatory and neurodegenerative disorders.

In a phase 2 study, sodium oxybate showed a significant, albeit short-lived, reduction in voice symptoms for patients with alcohol-responsive essential tremor of voice.

The double-blind, placebo-controlled study is expected to include 9 patients aged 35-75 years old with MSA-parkinsonian type who will be randomized 2:1 to either investigational AB-1005 or sham surgery.

Insurance coverage or cost was considered a barrier to prescribing novel NMOSD treatments in 42% of respondents, with the highest rate seen in eculizumab.

If successful, the study has potential implications for future surgical outcomes and patient experience among those with Parkinson disease.

Compared with placebo, treatment with ubrogepant 100 mg during the prodrome significantly reduced the development of moderate or severe headache for 24 hours after study-drug dose.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Brent Vaughan. [LISTEN TIME: 22 minutes]

Similar to the double-blind study, valbenazine was well-tolerated with clinically meaningful improvement in chorea severity after nearly a year of treatment.

Most of the studies included highlighted the increasing level of difficulty in all exercises performed and that the transition from one kinematic protocol to the other depended on the patient’s rate of improvement.

A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.

The research neuroscientist at the University of California Berkeley provided insight on findings from the US POINTER study and why previous thoughts on the link between relevant biomarkers and cognition may be slightly incorrect.

Neurofilament light, a marker of neuroaxonal damage, is correlated with increased levels of disease progression and clinical relapses.

The trial will feature 60 individuals with early-stage Parkinson disease who will be randomly assigned 1:1 to either daily CVN424 or placebo for a 12-week treatment period.

In addition to myasthenia gravis, KYV-101 is being explored in other disorders like systemic sclerosis, multiple sclerosis, and lupus nephritis.

Carbidopa levodopa enteral suspension for Parkinson disease demonstrated cost-effectiveness compared to standard care, with an incremental cost-effectiveness ratio of $7711/QALY in a real-world study.

Long-term nicotinamide riboside use in patients with ataxia telangiectasia showed safety, improved motor coordination, and eye movements, suggesting potential disease attenuation.